
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV demonstrates a promising outlook due to its strategic advancements in gene therapies, particularly with AMT-130 and AMT-191, which have gained credibility through recent updates and data from the WORLD 2026 conference. The increase in SG&A expenses to $21.6 million, up from $11.4 million year-over-year, reflects the company's commitment to bolster its clinical and operational capabilities as it prepares for potential product launches. Furthermore, the company’s robust pipeline addressing multiple genetic conditions and the adaptability of its balance sheet are seen as supporting factors that enhance investor confidence and indicate significant upside potential for uniQure’s stock.
Bears say
uniQure NV faces significant challenges due to intense market competition from both existing and emerging therapies that may hinder its ability to penetrate the market effectively and impact pricing strategies. As a clinical stage company, uniQure has yet to bring a revenue-generating product to market and has reported ongoing losses since its inception, indicating serious financial risks. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines could lead to prolonged development periods and increased costs, exacerbating the company's financial instability.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares